Abstracts tagged "Biomarkers"

Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0988 • ACR Convergence 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Sathej Gopalakrishnan¹, Axel Krebs-Brown², Marco Nogueira Filho¹, Yoshihiro Kuroki³, Angelika Bachmann¹, Andreas Becker¹, Frank Schippers⁴, Markus Fluck¹, Özkan Yalkinoglu¹, Christine Kleinmond⁵, Denesh Chitkara⁶, Cristina Vazquez Mateo⁷, Sanjeev Roy⁸ and Lena Klopp-Schulze¹, ¹Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany, ³Translational Medicine, Merck Biopharma Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, Tokyo, Japan, ⁴Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁵Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Global Clinical Development, EMD Serono, Billerica, MA, ⁷Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁸Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany
Background/Purpose: Enpatoran, a novel, highly selective and potent dual toll-like receptor (TLR) 7 and TLR8 inhibitor, is in development for the treatment of autoimmune disorders…
Abstract Number: 1249 • ACR Convergence 2022
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
Ahmad Almhdie-Imjabbar¹, Hechmi TOUMI², Zineb ZERZOUF³ and Eric LESPESSAILLES⁴, ¹University of Orleans / CHR Orleans, France, Orleans, Centre, France, ²Regional hospital centre of Orleans, France, Orleans, France, ³University of Tours, Tours, France, ⁴Regional hospital centre of Orleans, France, ORLEANS, Centre, France
Background/Purpose: Early detection and assessment of Knee Osteoarthritis (KOA) prognostic factors are crucial for developing management and treatments that aim at prevention of irreversible damage…
Abstract Number: 1501 • ACR Convergence 2022
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
Isaac Cheng¹, Martin Li², Ho SO¹, Jack Lee², Chun Kwok Wong² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic Arthritis (PsA) is a complex, heterogeneous disease with chronic inflammation. Disease manifestations include the peripheral joint inflammation, dactylitis, enthesitis and skin psoriasis. Chronic…
Abstract Number: 1706 • ACR Convergence 2022
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
Emmanuel Abimelec Camacho-Morán¹, jiram torres-Ruiz¹, Jaquelin Lira-Luna¹, Ana Sofía Vargas-Castro², Alfredo Pérez-Fragoso¹, Miroslava Nuñez-Aguirre², Beatriz Alcalá-Carmona³, Abdiel Absalón-Aguilar³ and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Post-COVID19 syndrome has been defined as the persistence of symptoms and/or organic damage for more than three weeks after the presence of clinical infection…
Abstract Number: 1906 • ACR Convergence 2022
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
Roxana Coras¹, Jessica Murillo Saich², Michal Hose Sanchez³, Anne Quan³, Emily Gentry¹, Pieter Dorrestein¹, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³VA San Diego Healthcare System, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Increasing evidence indicates that low grade systemic and local inflammation contributes to osteoarthritis (OA) progression. Bioactive lipid mediators are signaling molecules involved in inflammatory…
Abstract Number: 2108 • ACR Convergence 2022
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Stefan Siebert¹, Georg Schett², Siba P. Raychaudhuri³, Monica Guma⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷ and Proton Rahman⁸, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Memorial University, St. John's, NL, Canada
Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
Abstract Number: 2260 • ACR Convergence 2022
Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes
Shivmurat Yadav¹, Monika Niewiadomska¹, Lynsie Morris², Taylor Conner², Jessica Lumry², Sanique South³, Emmaline Prinz², Matlock Jeffries², Timothy Griffin², Stavros Stavrakis¹ and Mary Beth Humphrey¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Oklahoma Medical Research Foundation, Okahoma City, OK
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting over 32.5 million US adults and characterized by pain, stiffness, swelling and functional disability.…
Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…
Abstract Number: 0321 • ACR Convergence 2022
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
Eugene Krustev¹, John Hanly², Ricky Chin³, Katherine Buhler¹, Francesca S Cardwell⁴, Murray Urowitz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat İnanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵, Marvin Fritzler¹, Ann E Clarke³⁶ and May Choi³⁷, ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ³University of Calgary, Ottawa, ON, Canada, ⁴University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
Abstract Number: 0563 • ACR Convergence 2022
High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
Alisa Mueller¹, Takanori Sasaki², Joshua Keegan¹, Jennifer Nguyen¹, Alec Griffith¹, Elizabeth Feig¹, Alice Horisberger³, Ye Cao¹, Gregory Keras¹, Lauren Briere⁴, Laurel Cobban¹, Daimon Simmons¹, Juan Pallais¹, Jeffrey Sparks², V. Michael Holers⁵, Undiagnosed Diseases Network¹, David Sweetser⁴, Joel Krier¹, Joseph Loscalzo¹, James Lederer¹ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School and Lausanne University Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Colorado, Denver, CO
Background/Purpose: Few tools are available to evaluate the immune dysregulation in patients with severe autoimmune or inflammatory conditions that do not conform to well-defined rheumatologic…
Abstract Number: 0718 • ACR Convergence 2022
Biomarkers Predict Worsening of Lumbar Spine Degeneration and Low Back Pain: The Johnston County Osteoarthritis Project
Adam Goode¹, Rebecca Cleveland², Virginia Kraus¹, Steve George¹, Kenneth Taylor³, Todd Schwartz⁴, Jordan Renner⁴, Janet Huebner¹ and Yvonne Golightly⁵, ¹Duke University, Durham, NC, ²University of North Carolina, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴University of North Carolina- Chapel Hill, Chapel Hill, NC, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disc space narrowing (DSN) at the intervertebral disc and vertebral osteophyte (OST) formation are two potential sources of nociceptive lower back pain (LBP). The…
Abstract Number: 0990 • ACR Convergence 2022
KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
RAMESH C. GUPTA¹, Paul Lunseth², Robert Levin³, Philip Waller⁴, Amber Khan⁵, Lester Hernandez⁵, Kai Wei⁶, Baisong Liao⁶, Tao Wang⁷, Kaiyue Hao⁷, Yanjiao Yin⁷ and Yong Guo⁷, ¹Shelby Research LLC, Memphis, TN, ²Clinical Research of West Florida, Tampa, FL, ³Clinical Research of West Florida. Inc., Clearwater, FL, ⁴Accurate Clinical Research, Houston, TX, ⁵Accurate Clinical Management, LLC., Houston, TX, ⁶Kangpu Biopharmaceuticals, Ltd., Shanghai, China, ⁷Kangpu Biopharmaceuticals, Ltd, Shanghai, China
Background/Purpose: KPG-818 is a novel CRL4-CRBN E3 ubiquitin ligase modulator that binds to CRBN with high affinity and leads to rapid and effective degradation of…
Abstract Number: 1321 • ACR Convergence 2022
Systemic Inflammatory-based Scores and Bone Turnover Ratio as Novel Diagnostic Tools for Chronic Nonbacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region in Adults
Anne Leerling, Juliette Faber, Natasha Appelman-Dijkstra, Olaf Dekkers and Elizabeth Winter, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Chronic non-bacterial osteomyelitis (CNO) in adults exhibits as sterile osteitis and consequent disrupted bone metabolism favoring bone formation of the sternocostoclavicular region (SCCH). Diagnosis…
Abstract Number: 1508 • ACR Convergence 2022
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²University of California Davis, Sacramento, CA, ³UC Davis, School of Medicine, Sacramento, CA, ⁴VA Medical Center, Sacramento, CA
Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].